Trial Profile
A PHASE II STUDY OF SUNITINIB IN PATIENTS WITH ADVANCED HORMONE RESISTANT AND CHEMOTHERAPY RESISTANT PROSTATE CANCER.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2016
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 05 Oct 2016 New trial record